

EXHIBIT B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Sek Chung Fung <i>et al.</i>	Confirmation No.:	4825
Application No.:	10/583,927	Art Unit:	1643
Filed:	December 23, 2004	Examiner:	Rawlings, Stephen L.
For:	NOVEL ANTI-IL 13 ANTIBODIES AND USES THEREOF	Attorney Docket No.:	12279-187-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to reference B44 listed on the attached form entitled "List of References Cited by Applicant." A copy of reference B44 is submitted herewith.

Identification of the listed reference is not to be construed as an admission of Applicants or Attorneys for Applicants that such reference is available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

This Information Disclosure Statement is being filed after the period specified in 37 C.F.R. § 1.97(c), but on or before the payment of the issue fee. In accordance with 37 C.F.R. §§ 1.97(d)(1) and (e)(1), the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Pursuant to 37 C.F.R. § 1.704(d), the undersigned also hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.

In accordance with 37 C.F.R. §§ 1.97(d)(2) and 1.17(p), the fee required is estimated to be \$180.00. Please charge the required fee to Jones Day Deposit Account No. 50-3010. In the event an additional fee is required, please charge the additional fee to Jones Day Deposit Account No. 50-3013.

Date: October 10, 2011

Respectfully submitted,

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

by: Hong Ya Le
JONES DAY (Reg. No. 63767)
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

Sheet 1 of 1 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Application Number	10/583,927
	Filing Date	December 23, 2004
	First Named Inventor	Sek Chung Fung
	Art Unit	1643
	Examiner Name	Stephen L. Rawlings
	Attorney Docket No.	12279-187-999

U.S. PATENT DOCUMENTS					
*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B44	WO 2004/019975 A2	3/11/2004	Glaxo Group Limited		

NON PATENT LITERATURE DOCUMENTS					
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T

NYI-4403695v1

EXAMINER SIGNATURE	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	